专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2003048390A1 A PROCESS FOR THE PREPARATION OF A NON-TOXIC ANTHRAX VACCINE 审中-公开
标题翻译：制备非毒性ANTHRAX疫苗的方法
公开(公告)号：WO2003048390A1
公开(公告)日：2003-06-12
申请号：PCT/IN2002/000048
申请日：2002-03-20
申请人： BHATNAGAR, Rakesh , GUPTA, Pankaj , BATRA, Smriti , CHAUHAN, Vibha , SINGH, Aparna , AHUJA, Nidhi , KUMAR, Praveen
发明人： BHATNAGAR, Rakesh , GUPTA, Pankaj , BATRA, Smriti , CHAUHAN, Vibha , SINGH, Aparna , AHUJA, Nidhi , KUMAR, Praveen
IPC分类号： C12Q1/68
CPC分类号： C07K14/32 , A61K39/00
摘要： Anthrax toxin, comprising of protective antigen (PA), lethal factor (LF) and edema factor (EF) is a major virulent factor of B.anthracis . Protective antigen, PA is the main component of all the vaccines against anthrax. The protective efficacy of PA is greatly increased if small quantities of LF or EF are incorporated into the vaccines. An ideal vaccine against anthrax should contain PA, LF and EF together, but this combination would be toxic. Therefore, the biologically inactive mutant preparations of PA, LF and EF may be used together for better immunoprotection. The present invention describes the method for generation of recombinant vaccine against anthrax, comprising of non-toxic, mutant anthrax toxin proteins. The procedure involves site-directed mutagenesis of the native genes of the toxin proteins, the expression and purification of the mutant proteins and finally characterization of these proteins.
摘要翻译：由保护性抗原（PA），致死因子（LF）和水肿因子（EF）组成的炭疽毒素是甘蓝的主要毒性因子。保护性抗原，PA是所有针对炭疽疫苗的主要成分。如果将小量的LF或EF并入疫苗中，则PA的保护功效大大增加。针对炭疽的理想疫苗应包含PA，LF和EF，但这种组合是有毒的。因此，PA，LF和EF的生物活性突变体制剂可以一起用于更好的免疫保护。本发明描述了用于产生针对炭疽的重组疫苗的方法，其包含无毒的突变体炭疽毒素蛋白质。该方法涉及毒素蛋白质的天然基因的定点突变，突变蛋白的表达和纯化以及这些蛋白质的最终表征。

2. 发明申请

WO2003040179A1 HIGH LEVEL CONSTITUTIVE PRODUCTION OF ANTHRAX PROTECTIVE ANTIGEN 审中-公开
标题翻译： ANTHRAX保护性抗原的高水平生产
公开(公告)号：WO2003040179A1
公开(公告)日：2003-05-15
申请号：PCT/IN2001/000215
申请日：2001-12-07
申请人： BHATNAGAR, Rakesh , WAHEED, Syed, Mohsin , CHAUHAN, Vibha
发明人： BHATNAGAR, Rakesh , WAHEED, Syed, Mohsin , CHAUHAN, Vibha
IPC分类号： C07K14/32
CPC分类号： C07K14/32
摘要： The present invention relates to a process for preparing anthrax protective antigen protein from E.coli using fed batch culture. This process creates a constitutively expressing system for rapid, efficient, cost-effective and high-level production of anthrax PA from E.coli . The steps of the process involves, transforming E.coli DH5α cells with the recombinant constitutive expression plasmid containing the PA gene to obtain recombinant DH5α cells and testing the PA expression by lysis of said cells followed by denaturing gel electrophoresis and Western Blotting technique using PA antibodies. This is followed by fermentation and harvesting of the high cell density cells. The said cells are solubilized using 6-8 Molar Urea and separated by centrifugation. The urea denatured PA is isolated from said supernatant and purified and thereafter eluted.
摘要翻译：本发明涉及使用补料分批培养从大肠杆菌制备炭疽病保护性抗原蛋白的方法。该过程创建了一种组成型表达系统，用于从大肠杆菌中快速，高效，成本有效和高水平地生产炭疽芽孢杆菌。该方法的步骤包括用包含PA基因的重组组成型表达质粒转化大肠杆菌DH5α细胞以获得重组DH5α细胞，并通过裂解所述细胞测试PA表达，然后通过变性凝胶电泳和Western Blotting技术使用 PA抗体。随后发酵和收获高细胞密度的细胞。所述细胞用6-8摩尔尿素溶解并通过离心分离。尿素变性PA从所述上清液中分离并纯化，然后洗脱。

3. 发明申请

WO2009063507A1 DNA VACCINE AGAINST ANTHRAX 审中-公开
标题翻译： DNA疫苗反对ANTHRAX
公开(公告)号：WO2009063507A1
公开(公告)日：2009-05-22
申请号：PCT/IN2008/000761
申请日：2008-11-07
申请人： BHATNAGAR, Rakesh , MIDHA, Shuchi
发明人： BHATNAGAR, Rakesh , MIDHA, Shuchi
IPC分类号： A61K39/07 , C07K14/32
CPC分类号： C07K14/32 , A61K39/07 , A61K2039/53
摘要： The present invention relates to development of a DNA vaccine against anthrax using the protease-cleaved fragment of protective antigen. This fragment is operably linked to gene targeting cassette, either on N-terminal as a peptide leader or on C-terminal as a membrane anchoring tag or both. The gene targeting cassette will target the expressed antigen to various subcellular locations that will aid the processing and presentation of the antigen of interest through both the cellular antigen presentation pathways which would result in an enhanced immune response against protective antigen.
摘要翻译：本发明涉及使用保护性抗原的蛋白酶切割片段开发针对炭疽的DNA疫苗。该片段与基因靶向盒可操作地连接，作为肽前导体的N-末端或作为膜锚定标签的C-末端或两者。基因靶向盒将靶向表达的抗原到各种亚细胞位置，这将有助于通过细胞抗原呈递途径处理和表达感兴趣的抗原，这将导致针对保护性抗原的增强的免疫应答。

4. 发明申请

WO2009153801A1 DNA VACCINE BASED ON GLYCOPROTEIN GENE OF RABIES VIRUS CONJUGATED TO LAMP-1 SIGNAL SEQUENCE AT THE C-TERMINUS AND AN ADJUVANT; AND METHOD OF ITS PREPARATION THEREOF 审中-公开
标题翻译：基于与C-TERMINUS和ADJUVANT的LAMP-1信号序列相关的RABIES病毒的GLYCOPROTEIN基因的DNA疫苗; 及其制备方法
公开(公告)号：WO2009153801A1
公开(公告)日：2009-12-23
申请号：PCT/IN2008/000578
申请日：2008-09-10
申请人： KAUR, Manpreet , RAI, Anant , BHATNAGAR, Rakesh
发明人： KAUR, Manpreet , RAI, Anant , BHATNAGAR, Rakesh
IPC分类号： C07K14/145 , A61K39/205
CPC分类号： A61K39/205 , A61K39/12 , A61K2039/53 , A61K2039/55566 , A61K2039/6031 , C07K14/005 , C07K2319/06 , C12N2760/20122 , C12N2760/20134
摘要： A pharmaceutical composition of vaccine against rabies, which comprises of DNA vaccine based on glycoprotein gene of rabies virus conjugated to LAMP-1 signal sequence at the C-terminus, and an adjuvant; and method of its preparation thereof.
摘要翻译：一种针对狂犬病疫苗的药物组合物，其包含基于在C-末端与LAMP-1信号序列缀合的狂犬病病毒糖蛋白基因的DNA疫苗和佐剂; 及其制备方法。

5. 发明申请

WO2011117886A1 BISPECIFIC MONOCLONAL ANTIBODY CAPABLE OF CROSS REACTING WITH LETHAL FACTOR (LF) AND EDEMA FACTOR (EF), AND NEUTRALIZING EDEMA TOXIN (ET) AS WELL AS LETHAL TOXIN (LT) OF BACILLUS ANTHRACIS 审中-公开
标题翻译：双重反应性单核细胞抗体可以与纤维蛋白原（LF）和EDEMA因子（EF）交联反应，并且中和（如ET）作为BACILLUS ANTHRACIS的低毒素（LT）
公开(公告)号：WO2011117886A1
公开(公告)日：2011-09-29
申请号：PCT/IN2011/000191
申请日：2011-03-22
申请人： BHATNAGAR, Rakesh , KULSHRESHTHA, Parul
发明人： BHATNAGAR, Rakesh , KULSHRESHTHA, Parul
IPC分类号： C07K16/12 , A61K39/395 , A61P31/00
CPC分类号： C07K16/1278 , A61K2039/505 , C07K2317/33 , C07K2317/76
摘要： The present invention relates to a monoclonal antibody (mAb) having capabilities of binding with lethal factor (LF) as well as edema factor (EF), and neutralizing lethal toxin (LT) as well as edema toxin (ET) of B. anthracis . It also relates to process for preparation of said mAb, and to pharmaceutical preparations, anthrax diagnostic tool, in-vivo diagnostic imaging tool comprising said mAb. It also relates to genetically modified mAb, and method for prophylaxis against anthrax disease comprising administration of mAb or genetically modified mAb of present invention.
摘要翻译：本发明涉及具有与致死因子（LF）以及水肿因子（EF）和中和致死毒素（LT）以及炭疽芽孢杆菌的水肿毒素（ET）结合的能力的单克隆抗体（mAb）。还涉及制备所述mAb的方法，以及药物制剂，炭疽诊断工具，包含所述mAb的体内诊断成像工具。它还涉及遗传修饰的mAb，以及用于预防炭疽病的方法，包括施用本发明的mAb或遗传修饰的mAb。

6. 发明申请

WO2010073257A1 AN IMMUNODOMINANT B-CELL EPITOPE BASED PROTEIN VACCINE AGAINST ANTHRAX AND METHOD OF PREPARATION THEREOF 审中-公开
标题翻译：一种免疫抑制剂B细胞抗原决定蛋白疫苗对其抗性的制备及其制备方法
公开(公告)号：WO2010073257A1
公开(公告)日：2010-07-01
申请号：PCT/IN2009/000230
申请日：2009-04-08
申请人： KAUR, Manpreet , CHUG, Hema , BHATNAGAR, Rakesh
发明人： KAUR, Manpreet , CHUG, Hema , BHATNAGAR, Rakesh
IPC分类号： G06F19/00 , C07K16/12 , A61K38/16 , A61P31/04
CPC分类号： C07K16/1278 , A61K39/07 , A61K2039/53 , A61K2039/55566 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to the development of immunodominant B-cell epitope based protein vaccine having SEQ ID No.: 1 eliciting immune response against anthrax. The invention also relates to a polynucleotide sequence having SEQ ID No.: 2 encoding epitope based protein vaccine. The invention also relates to the method of preparation and purification of epitope based protein vaccine. The present invention further relates to vaccine composition of B-cell epitope based protein vaccine against anthrax, its method of preparation and process of using the composition. The vaccine or the vaccine composition of the present invention generates high titers of antibodies having high affinity and avidity and are highly effective in in vitro neutralization of B . anthracis lethal toxin and conferring protection against in vivo lethal toxin challenge.
摘要翻译：本发明涉及具有SEQ ID No .: 1的免疫优势B细胞表位蛋白疫苗的开发，引发针对炭疽的免疫应答。本发明还涉及具有SEQ ID No.2.2编码基于表位的蛋白质疫苗的多核苷酸序列。本发明还涉及基于表位的蛋白质疫苗的制备和纯化方法。本发明还涉及针对炭疽的B细胞表位蛋白疫苗的疫苗组合物，其制备方法和使用该组合物的方法。本发明的疫苗或疫苗组合物产生具有高亲和力和亲合力的高滴度抗体，并且在体外中和炭疽杆菌致死毒素方面具有高度有效性，并且赋予针对体内致死毒素攻击的保护作用。

7. 发明申请

WO2008142707A3 INSECTICIDAL XNGROEL PROTEIN OF XENORHABDUS NEMATOPHILA 审中-公开
公开(公告)号：WO2008142707A3
公开(公告)日：2008-11-27
申请号：PCT/IN2008/000316
申请日：2008-05-19
申请人： JOSHI, Mohan, Chandra , SHARMA, Animesh , BIRAH, Ajanta , GUPTA, Gorakh, Prasad , BANERJEE, Nirupama , BHATNAGAR, Rakesh
发明人： JOSHI, Mohan, Chandra , SHARMA, Animesh , BIRAH, Ajanta , GUPTA, Gorakh, Prasad , BANERJEE, Nirupama , BHATNAGAR, Rakesh
IPC分类号： C07K14/24 , A01N63/02
摘要： The present invention relates to a novel insecticidal protein named XnGroEL isolated and purified from Xenorhabdus nematophila having GENE BANK ACCESSION No. AY18449. The process for the purification of novel insecticidal protein named XnGroEL is also disclosed. The invention also relates to the process for preparation and purification of the recombinant novel insecticidal XnGroEL protein. The process involves purification of a novel insecticidal protein Xenorhabdus nematophila, construction of genomic DNA library, screening of library using probes with N-terminal amino acid sequence, cloning in an expression vector followed by its transformation in E. coli cells and purification of the recombinant protein. Both the novel native and recombinant insecticidal XnGroEL protein have growth inhibitory and insecticidal property for Helicoυerpa armigera larvae. The present invention also discloses that the novel native and recombinant insecticidal XnGroEL protein has larval gut brush border membrane vesicles binding activity and α-chitin binding activity.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式